Țară: Irlanda
Limbă: engleză
Sursă: HPRA (Health Products Regulatory Authority)
Levetiracetam
Brillpharma (Ireland) Limited
N03AX; N03AX14
Levetiracetam
100 milligram(s)/millilitre
Oral solution
Other antiepileptics; levetiracetam
Not marketed
2017-03-24
1 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT LEVETIRACETAM BRILLPHARMA 100 MG/ML ORAL SOLUTION LEVETIRACETAM READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU OR YOUR CHILD START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Levetiracetam Oral Solution is and what it is used for 2. What you need to know before you take Levetiracetam Oral Solution 3. How to take Levetiracetam Oral Solution 4. Possible side effects 5. How to store Levetiracetam Oral Solution 6. Contents of the pack and other information 1. WHAT LEVETIRACETAM ORAL SOLUTION IS AND WHAT IT IS USED FOR The name of your medicine is Levetiracetam 100mg/ml Oral Solution and is referred as ‘Levetiracetam Oral Solution’ throughout the leaflet. Levetiracetam 100 mg/ml Oral Solution is an antiepileptic medicine (a medicine used to treat seizures in epilepsy). Levetiracetam is used: • on its own in adults and adolescents from 16 years of age with newly diagnosed epilepsy, to treat a certain form of epilepsy. Epilepsy is a condition where the patients have repeated fits (seizures). Levetiracetam is used for the epilepsy form in which the fits initially affect only one side of the brain, but could thereafter extend to larger areas on both sides of the brain (partial onset seizure with or without secondary generalisation). Levetiracetam has been given to you by your doctor to reduce the number of fits. • as an add-on to other antiepileptic medicines to treat: - partial onset seizures with or without generalisation in adults, adolescents, children and infants from one month of age Citiți documentul complet
Health Products Regulatory Authority 02 July 2021 CRN00CD72 Page 1 of 16 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Levetiracetam Brillpharma100 mg/ml Oral Solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of solution contains 100 mg Levetiracetam. Excipients with known effect: Each ml of solution contains 1.5 mg of methyl parahydroxybenzoate (E218), 0.18 mg of propyl parahydroxybenzoate (E216) and 300 mg of liquid maltitol. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Oral solution A clear, colourless grape flavoured liquid. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Levetiracetam is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy. Levetiracetam is indicated as adjunctive therapy: in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents, children and infants from 1 month of age with epilepsy. in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Monotherapy for adults and adolescents from 16 years of age_ The recommended starting dose is 250 mg twice daily which should be increased to an initial therapeutic dose of 500 mg twice daily after two weeks. The dose can be further increased by 250 mg twice daily every two weeks depending upon the clinical response. The maximum dose is 1500 mg twice daily. _Add-on therapy for adults (≥ 18 years) and adolescents (12 to 17 years) weighing 50 kg or more_ The initial therapeutic dose is 500 mg twice daily. This dose can be started on the first day of treatment. Depending upon the clinical response and tolerability, the daily dose can be increased u Citiți documentul complet